Skip to main content

We are delighted to announce Tenovus Cancer Care/Gofal Canser as our UK charity partner for 2019.

The partnership will span over two years and we hope to raise £4500, which will help fund:

  • Chemotherapy treatment for 100 people at mobile support units.
  • Training for 900 people to advise school children in sun safety.
  • Their free and confidential support line.

We believe it’s important to support charitable causes within our local community that make a real difference. We chose Tenovus as our first UK charity partnership because we know they do just that. It’s a well-known and loved organisation doing great work in Wales and many of our Cardiff team have direct links with the charity and its cause.

Tenovus Cancer Care’s vision is a future where fewer people get cancer, and those that do have equal access to the best treatment and support.

The charity brings treatment, emotional support and practical advice to where it matters most: the heart of the local community. They also promote healthy lifestyles and fund cancer research to find new ways to prevent it, diagnose it, and treat it.  A cancer diagnosis can have a huge impact on most patients, families, and caregivers. We’re proud to lend our support to help cancer patients and their loved ones, where and when they need may need it most.

Carys Jenkins, Corporate Relationship Manager, Tenovus “It’s an exciting time for us as a charity to be partnering with Bipsync, who are a rapidly growing company in Cardiff, as we look forward to engaging with their staff on a variety of fundraising activities over the year to come. They’re an ambitious team who have already agreed to make their miles matter for cancer patients, by taking on a sponsored cycle from Brecon to Cardiff and we’ve no doubt they’ll smash their fundraising goal.”

We have plenty of exciting plans in the pipeline, starting with the Brecon to Cardiff bike ride, and are confident our target of £4500 will be achieved so we can help support Tenovus in all their amazing work.